EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
183.93
-0.71 (-0.38%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close184.64
Open184.55
Bid183.52 x 800
Ask183.52 x 900
Day's Range182.49 - 184.63
52 Week Range134.53 - 197.86
Volume1,077,939
Avg. Volume1,234,509
Market Cap38.35B
Beta (3Y Monthly)0.96
PE Ratio (TTM)51.12
EPS (TTM)3.60
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est193.11
Trade prices are not sourced from all markets
  • Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam
    Investor's Business Daily3 days ago

    Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam

    A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.

  • Read This Before Buying Edwards Lifesciences Corporation (NYSE:EW) Shares
    Simply Wall St.4 days ago

    Read This Before Buying Edwards Lifesciences Corporation (NYSE:EW) Shares

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • HOLX or EW: Which Is the Better Value Stock Right Now?
    Zacks4 days ago

    HOLX or EW: Which Is the Better Value Stock Right Now?

    HOLX vs. EW: Which Stock Is the Better Value Option?

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.

    Edwards Lifesciences Corp NYSE:EWView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for EW with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EW had net inflows of $1.66 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • DexCom and Companion Medical Collaboration to Support CGM
    Zacks10 days ago

    DexCom and Companion Medical Collaboration to Support CGM

    The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.

  • Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire13 days ago

    Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    IRVINE, Calif. , June 4, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Benzinga13 days ago

    The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...

  • Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
    PR Newswire14 days ago

    Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation

    IRVINE, Calif., June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the company's outstanding shares of common stock as of the date of the offer. Edwards does not endorse this unsolicited offer and recommends that the company's stockholders reject the offer, either by doing nothing in response or by withdrawing their shares from the offer, if they have responded. Edwards is not affiliated or associated in any way with TRC Capital, its mini-tender offer or the offer documentation.

  • Why We Like Edwards Lifesciences Corporation’s (NYSE:EW) 23% Return On Capital Employed
    Simply Wall St.19 days ago

    Why We Like Edwards Lifesciences Corporation’s (NYSE:EW) 23% Return On Capital Employed

    Today we'll evaluate Edwards Lifesciences Corporation (NYSE:EW) to determine whether it could have potential as an...

  • Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?
    Zacks25 days ago

    Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?

    Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Edwards Announces Milestones For Transcatheter Mitral Program
    PR Newswire26 days ago

    Edwards Announces Milestones For Transcatheter Mitral Program

    Today at the EuroPCR annual course in Paris, new 6-month data from the CLASP study of the PASCAL system were presented by Konstantinos Spargias, M.D., from the Hygeia Hospital in Athens, Greece.  Patients enrolled in the CLASP study had clinically significant mitral regurgitation (MR) despite optimal medical therapy.  The results from treatment with the PASCAL system demonstrated sustained positive outcomes at six months, including 81 percent of patients with mild (1+) or none/trace MR and 98 percent with 2+ MR, with echo core lab adjudication.  Patients experienced clinically and statistically significant improvements in functional status, exercise capability and quality of life sustained at six months.

  • HOLX vs. EW: Which Stock Is the Better Value Option?
    Zacks28 days ago

    HOLX vs. EW: Which Stock Is the Better Value Option?

    HOLX vs. EW: Which Stock Is the Better Value Option?

  • Top 5 Health Care Stocks of 2018 by Performance
    Investopedia29 days ago

    Top 5 Health Care Stocks of 2018 by Performance

    The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.

  • Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
    PR Newswirelast month

    Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020

    IRVINE, Calif., May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on schedule to meet its goal of impacting the global burden of heart valve disease. The initiative, which involves the education, screening and treatment of 1.5 million underserved people by 2020, is supported by grants from Edwards Lifesciences Foundation, donations of Edwards heart valve technologies, volunteer support and the dedicated work of 60 non-profit partners. "Since the Every Heartbeat Matters initiative began five years ago, we have made substantial progress in building a global community that is addressing the burden of heart valve disease for underserved people," said Amanda Fowler, executive director, Edwards Lifesciences Foundation.

  • Bull of the Day: Penumbra (PEN)
    Zackslast month

    Bull of the Day: Penumbra (PEN)

    Bull of the Day: Penumbra (PEN)

  • GuruFocus.comlast month

    Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5.9 million of Shares

    Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 05/10/2019 at an average price of $178.99 a share.

  • Investors Who Bought Edwards Lifesciences (NYSE:EW) Shares Five Years Ago Are Now Up 314%
    Simply Wall St.last month

    Investors Who Bought Edwards Lifesciences (NYSE:EW) Shares Five Years Ago Are Now Up 314%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
    PR Newswirelast month

    Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue

    TORONTO, May 7, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards' bioprosthetic surgical aortic valves featuring the company's novel RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up, with no events of structural valve deterioration (SVD). The COMMENCE study enrolled 694 patients, 144 (21 percent) of which were under the age of 60 when they had surgical valve replacement.

  • Masimo Gets CE Mark for ANI Module, Enhances Root Platform
    Zacks2 months ago

    Masimo Gets CE Mark for ANI Module, Enhances Root Platform

    Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.

  • Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
    PR Newswire2 months ago

    Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

    IRVINE, Calif. , May 1, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • GuruFocus.com2 months ago

    Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5.7 million of Shares

    Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 04/29/2019 at an average price of $174.73 a share.

  • 5 Peter Lynch Stalwarts With Strong Operating Margins
    GuruFocus.com2 months ago

    5 Peter Lynch Stalwarts With Strong Operating Margins

    Dallas-based vehicle auctioneer tops list of stalwarts in terms of operating margin

  • Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
    Zacks2 months ago

    Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised

    Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of EW earnings conference call or presentation 23-Apr-19 9:00pm GMT

    Q1 2019 Edwards Lifesciences Corp Earnings Call